NattoPharma raises $3.0 million in new equity

NattoPharma, a privately-held Norwegian nutraceutical company based in Oslo, selling and developing products containing the natural vitamin K2, has completed a public retail and institutional offering that raised 16.4 million Norwegian kroner ($3.0 million) in new equity.

The board of directors of the firm has resolved to approve the subscription of new shares of 1.367.924, each with a face value of 0.10 kroner. The subscription price per share is 12 kroner, which equals about 16.4 million kroner in increased equity. 136,792.40 kroner will be registered as new share capital while some 16.3 million kroner will be registered as share premium reserve. The placement was completed on January 4.

After the completion of the retail and institutional offering, including 300.000 shares subscribed by Eng AS as part of an option scheme offered in 2006 and declared and paid in December 17, 2007, there are now 20,445,224 shares outstanding in NattoParma ASA, each with a face value of 0.10 kroner, which is equal to a share capital of about 2.0 million kroner.